This summary article helps explain the results of Deciphera's Phase 3 INTRIGUE trial as published in Future Medicine, authored by Marina Symcox & Robin L Jones.
The NCCN updated the clinical practice guidelines in oncology for GIST and other cancers in April and now have released the patient guidelines. Find the links here.
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
Deciphera issued a press release today sharing the results of an exploratory analysis of data using circulating tumor DNA (ctDNA) from the INTRIGUE Phase 3 clinical study of ripretinib and announcing plans to initiate INSIGHT.
Recent articles have shed light on an issue of concern about counterfeits for patients who take imatinib myselate as part of their treatment for GIST.
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.
Concerning Medicare Open Enrollment: It is especially important for GIST patients to carefully consider available plans, as one of the financial support resources that has been available through Novartis Pharmaceuticals will end on January 1, 2021.
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.